China’s First CAR-T Trial: “Pay-for-Performance” Introduced!

CAR-T

This means that eligible patients using Fosun Kite’s #CARTtherapy, #Axicabtagene Ciloleucel, will undergo effectiveness assessment three months after drug purchase and infusion. If complete remission (CR) is not achieved, patients will receive a refund of up to ¥600,000(RMB)!

is not only China’s first for lymphoma drugs but also the country’s first for bio-innovative drugs!

is an immunotherapy method that involves genetically modifying a patient’s T cells outside the body to recognize specific tumor targets before reinfusing them to precisely combat #tumors. Currently, five products, including Fosun Kite’s #AxicabtageneCiloleucel, have been approved domestically.

     As a form of immunotherapy, CAR-T cell therapy works by collecting a patient’s T cells and genetically modifying them outside the body to recognize specific tumor targets. These modified T cells are then reintroduced into the patient, enabling precise targeting and attacking of tumors. Currently, there are five approved products domestically, including Axicabtagene Ciloleucel from Fosun Kite, Relmacabtagene Autoleucel from JW Therapeutics, Equecabtagene Autoleucel from IASO Bio, Inaticabtagene Autoleucel from Juventas, and Zevorcabtagene autoleucel from CARsgen.

Unlike traditional drugs, CAR-T requires individualized production for each patient, thus incurring higher costs. However, this innovative pay-for-performance model brings new hope to patients!

Fosun Kite’s project leader stated that they will collaborate with clinical experts, health commissions, treatment demonstration centers, and other stakeholders to establish “Cure” standards, objectively assessing lymphoma efficacy. This will provide reliable evaluation criteria for performance-based payment!